MYGN Expands Cancer Test
Myriad Genetics expands availability of Precise MRD for colorectal, renal, and breast cancers
MYGN - Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New PublicationPublication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD